VOGLIBOSE(An Anti- Diabetic Agent)Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levelsin people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reduces therisk of macrovascular complications. Voglibose is a research product of Takeda Pharma, a Japanbased company.Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alphaglucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent suddensurge of glucose after a meal.There are three drugs which belong to this class, acarbose, miglitoland voglibose, of which voglibose is the newest. Voglibose scores over both acarbose andmiglitol in terms of side effect profile. But acarbose has an edge over voglibose in terms ofefficacy (FPG, PPHG, HBA1c).Chemical FormulaC10-H21-N-O7Molecular Weight267Therapeutic CategoryOral antidiabetic agent: Alpha-glucosidase inhibitorChemical Name3,4-Dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epiinositolIndication&Dosage: Oral Diabetes mellitusAdult: 200-300 mcg tid.Elderly: Initiate at lower doses.Administration: Should be taken with food. Take just before meals.
Mechanism of Action: Voligbose has general properties similar to acarbose and selectivelyinhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate,thereby suppressing sharp increase in post-prandial plasma glucose.Contraindications :Inflammatory bowel disease; GI obstruction or patients predisposed to it;conditions which may deteriorate as a result of increased gas formation eg, hernia; severeketosis; diabetic coma or pre-coma; severe infection; hypersensitivity; pregnancy; lactation. Notto be used as monotherapy in IDDM.Special Precautions: History of laparotomy or ileus. Roemhelds syndrome, stenosis, severehepatic or renal impairment. Child <18 yr; elderly. Monitor LFT. Treat hypoglycaemic episodeswith glucose (not with sucrose).Adverse Drug Reactions :Flatulence; abdominal distension; diarrhoea; pain; skinreactions;hypoglycemia; increased LFT.Potentially Fatal: Hepatotoxicity. Drug Interactions May enhance effects of other antidiabeticsincluding insulin.Storage: Oral: Store below 30°C.